Collegium Pharmaceutical Reports Strong Q2 2025 Results

Collegium Pharmaceutical Inc. ( (COLL) ) has released its Q2 earnings. Here is a breakdown of the information Collegium Pharmaceutical Inc. presented to its investors.

Collegium Pharmaceutical Inc., a biopharmaceutical company based in Stoughton, Massachusetts, specializes in pain management medications and neuropsychiatry treatments, notably Jornay PM for ADHD. In its latest earnings report, Collegium announced record quarterly net revenue of $188 million, marking a 29% increase year-over-year. The company also reported significant growth in its ADHD medication, Jornay PM, with net revenue reaching $32.6 million, a 23% increase in prescriptions year-over-year. Additionally, the pain portfolio generated $155.4 million in net revenue, a 7% increase from the previous year.

Collegium has raised its full-year 2025 net revenue guidance to a range of $745 to $760 million and adjusted EBITDA guidance to $440 to $455 million. The company ended the second quarter with $222.2 million in cash, cash equivalents, and marketable securities. The Board of Directors has authorized a $150 million share repurchase program, further demonstrating the company’s commitment to enhancing shareholder value.

The company’s financial performance was bolstered by a 9% year-over-year increase in adjusted EBITDA, reaching $105.1 million for the quarter. Despite a decrease in GAAP net income to $12 million from $19.6 million in the previous year, non-GAAP adjusted net income remained strong at $64.3 million. The company continues to focus on strategic capital deployment and business development opportunities to expand its portfolio.

Looking ahead, Collegium anticipates a strong second half of the year, particularly for Jornay PM, as it prepares for the back-to-school season. The company remains focused on driving top- and bottom-line growth while serving patients with serious medical conditions.